deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
In 1955, Soviet paleontologist Evgeny Maleev named a new species, Tyrannosaurus bataar, from Mongolia. By 1965, this species was renamed as a distinct genus, Tarbosaurus bataar. While most paleontologists continue to maintain the two as distinct genera, some authors such as Thomas Holtz, Kenneth Carpenter, and Thomas Carr argue that the two species are similar enough to be considered members of the same genus, restoring the Mongolian taxon's original binomial name. Some specimens from the Late Cretaceous deposits of China have been described as new species of Tyrannosaurus: T. "lanpingensis" based on isolated lateral tooth from the red beds of Yunnan in 1975; T. "turpanensis" from the Subashi Formation, Turpan Basin, Xinjiang in 1978; and T. luanchuanensis from the Quiba Formation in Henan Province in 1979–1980. The former two taxa were published without detailed descriptions and are therefore nomina nuda. T. "turpanensis" and T. luanchuanensis were tentatively listed as junior synonyms of Tarbosaurus bataar by Holtz in 2004; Holtz also listed T. "lanpingensis," but as a nomen dubium. VGI, no. 231/3, a large phalanx bone, assigned to Tyrannosaurus sp. by Yarkov in 2000, was found in the Lower Maastrichtian of Bereslavka, Russia. In 2004, Averianov and Yarkov reinterpreted it as a metacarpal or metatarsal that possibly belongs to ceratosaur. In their 2023 overview, Averianov and Lopatin mention this specimen as well as a single tooth from the same site only as Theropoda indet.
==== Type IV ==== Collagen quantity is sufficient, but it is not of a high enough quality. Type IV is for cases of variable severity, which do not fit into either types III or I. While one of Sillence's required characteristics for type IV was having normal sclerae, modern classification allows even those with blue sclerae to fit the criteria for type IV if they meet the other clinical requirements of the type. In type IV, bone deformity can be mild to severe, bones fracture easily (especially before puberty), dwarfism is common, vertebral collapse and scoliosis are evident, and hearing loss is possible, although uncommon. Type IV OI is mostly defined in contrast to type III and type I, being the clinical classification for patients somewhere in the middle ground between the two. As such, type IV OI is often termed "variable" OI, with the severity of even those in the same family (so, with the same genetic mutation) differing. Prepubertal bone fracture rates are another way of clinically assessing type IV OI—those with it tend to have fracture rates of ≈1 per year, compared to ≈3 per year for severe OI (type III). As in type I, some further split type IV into types IV–A and IV–B, defined again by the absence (IV–A) or presence (IV–B) of dentinogenesis imperfecta.
239Pu(16O,xn)255−xNo This reaction was first studied in 1958 at the FLNR. The team were able to measure ~8.8 MeV alpha particles with a half-life of 30 s and assigned to253,252,251102. A repeat in 1960 was unsuccessful and it was concluded the first results were probably associated with background effects.
Sources: en.wikipedia.org
Nir Ben-Tal [NBT1] (Hebrew: ניר בן-טל) is an Israeli computational biologist and professor in the School of Neurobiology, Biochemistry and Biophysics of the George S. Wise Faculty of Life Sciences, Tel Aviv University. He holds the Abraham E. Kazan Chair of Structural Biology, Tel Aviv University. His research focuses on computational structural biology, structural bioinformatics, protein evolution, and the relationships among protein sequence, structure, dynamics, and function.
=== Commanding officers === 1950 Lt Col Mike Calvert, Royal Engineers 1951 Lt Col John Sloane, Argyll and Sutherland Highlanders 1953 Lt Col Oliver Brooke, Welch Regiment 1954 Lt Col Michael Osborn, West Yorkshire Regiment 1955 Lt Col George Lea, Lancashire Fusiliers and Parachute Regiment 1957 Lt Col Tony Deane-Drummond, Royal Signals 1960 Lt Col Ronald Dare Wilson, Royal Northumberland Fusiliers 1962 Lt Col John Woodhouse, Dorset Regiment and East Surreys 1965 Lt Col Michael Wingate-Gray, Black Watch 1967 Lt Col John Slim, Argyll and Sutherland Highlanders 1969 Lt Col John Watts, Royal Irish Rangers 1972 Lt Col Peter de la Billière, Light Infantry 1974 Lt Col Anthony Jeapes, Devonshire and Dorset Regiment 1977 Lt Col Mike Wilkes, Royal Artillery 1982 Lt Col Mike Rose, Coldstream Guards 1984 Lt Col Andrew Massey, Royal Corps of Transport 1986 Lt Col Cedric Delves, Devonshire and Dorset Regiment 1989 Lt Col John Holmes, Scots Guards n/k Lt Col Jonathan "Jacko" Page, Parachute Regiment 2001 Lt Col Ed Butler, Royal Green Jackets 2002 Lt Col Mark Carleton-Smith, Irish Guards 2007 Lt Col Richard Williams, Parachute Regiment 2012 Lt Col Nick Perry, King's Royal Hussars
Plants that cause illness or death after consuming them are referred to as poisonous plants. The toxins in poisonous plants affect herbivores, and deter them from consuming the plants. Plants cannot move to escape their predators, so they must have other means of protecting themselves from herbivorous animals. Some plants have physical defenses such as thorns, spines and prickles, but by far the most common type of protection is chemical. Over millennia, through the process of natural selection, plants have evolved the means to produce a vast and complicated array of chemical compounds to deter herbivores. Tannin, for example, is a defensive compound that emerged relatively early in the evolutionary history of plants, while more complex molecules such as polyacetylenes are found in younger groups of plants such as the Asterales. Many of the known plant defense compounds primarily defend against consumption by insects, though other animals, including humans, that consume such plants may also experience negative effects, ranging from mild discomfort to death. Many of these poisonous compounds also have important medicinal benefits. The varieties of phytochemical defenses in plants are so numerous that many questions about them remain unanswered, including:
Sources: en.wikipedia.org
==== Suicide ==== LSD has led to suicide weeks or months after ingestion. LSD was originally categorized as a schedule I controlled substance because of the suicide of Diane Linkletter 6 months after she took LSD. There are several case reports of suicidal reactions to LSD.
Generation of Neutralizing Human Monoclonal Antibodies Against a Therapeutic Target from the Alloy Therapeutics Mouse Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms Development of Antibody and PK, and ADA Assays for a Cystine Knot Fusion Protein A Rapid, High-Throughput Recombinant Antibody Expression System for Therapeutic Antibody Discovery and Validation Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse Generation and Selection of Human Monoclonal Antibodies from the OmniRat Therapeutic Antibody Discovery at Antibody Solutions using the OmniAb Platform Development of human antibodies to human vascular endothelial growth factor -C (VEGF-C) and -D (VEGF-D) Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization Next-Generation Therapeutic Antibody Discovery from Single B-cells Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse Generation of Antibodies to Difficult Membrane Protein Targets Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63 Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
Another influence is over-hunting and poaching, which can reduce the overall population of game animals, especially those located near villages, as in the case of peccaries. The effects of poaching can especially be seen in the ivory trade with African elephants. Marine mammals are at risk from entanglement from fishing gear, notably cetaceans, with discard mortalities ranging from 65,000 to 86,000 individuals annually. Attention is being given to endangered species globally, notably through the Convention on Biological Diversity, otherwise known as the Rio Accord, which includes 189 signatory countries that are focused on identifying endangered species and habitats. Another notable conservation organization is the IUCN, which has a membership of over 1,200 governmental and non-governmental organizations. Recent extinctions can be directly attributed to human influences. The IUCN characterizes 'recent' extinction as those that have occurred past the cut-off point of 1500, and around 80 mammal species have gone extinct since that time and 2015. Some species, such as the Père David's deer are extinct in the wild, and survive solely in captive populations. Other populations, such as the Florida panther, are ecologically extinct, surviving in such low numbers that they essentially have no impact on the ecosystem. Other populations are only locally extinct (extirpated), still existing elsewhere, but reduced in distribution, as with the extinction of gray whales in the Atlantic.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.